U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer ...

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...

Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

After its success in treating blood cancers: CAR-T Therapy is now purposed to treat autoimmune disease, Lupus. -p -p ...

Presbyterian Healthcare Services recently unveiled the HALL, a 25,200-square-foot learning lab dedicated to giving health care workers a space to learn new skills while enhancing old skills. The $6 ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

Officially Benefiting Mainland China PatientsSHANGHAI, Dec 18, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

REGIONS NEWS Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially ...